EQT Life Sciences to exit minority stake in Tubulis via sale to Gilead Sciences for up to USD 5.0 billion

Summary

Gilead Sciences has entered into a definitive agreement to acquire Tubulis, a private German clinical-stage biotechnology company, for up to USD 5.0 billion. EQT Life Sciences is exiting its minority stake in Tubulis through the transaction following its Series B2 financing leadership in March 2024.